FORMULATION AND DEVELOPMENT OF NOVEL AND STABLE DOSAGE FORMS OF LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS BY WET GRANULATION TECHNIQUE
AbstractAntiretroviral drugs are medications used for treatment of infection caused by retroviruses, primarily HIV. Different classes of antiretroviral drugs act at different stages of the HIV life cycle. No individual antiretroviral drug has been demonstrated to suppress an HIV infection for prolong treatment. Antiretroviral drugs must be taken in combinations in order to have a lasting effect. Combination of several (typically two or three or four) antiretroviral drugs were known to be defined as Highly Active Anti-Retroviral Therapy (HAART). These combinations create multiple obstacles to HIV replication to keep the number of offspring low and reduce the possibility of a superior mutation. If a mutation that conveys resistance to one of the drugs being taken arises, the other drugs continue to suppress reproduction of that mutation. In our Present study we aimed to develop a Stable Pharmaceutical dosage form with two different anti-retroviral drugs Lamivudine and Tenofovir Disoproxil Fumarate. Lamivudine and Tenofovir Disoproxil Fumarate were classified as High soluble and low permeable (BCS class 3) As per BCS classification system.
Article Information
56
3538-3542
335
1028
English
IJPSR
C. S. Panchagnula *, N. B. Naware, S. S. Bhamre, K. D. Deo and S. Meenakshisunderam
Polygen Pharmaceuticals Inc., 41 - 17, Mercedes Way, Edgewood, New York, USA.
chandrasekharp@polygenpharma.com
06 November, 2017
19 January, 2018
06 February, 2018
10.13040/IJPSR.0975-8232.9(8).3538-42
01 August, 2018
Download